PB2021: PHASE 2 STUDY OF ORAL DECITABINE/CEDAZURIDINE IN COMBINATION WITH MAGROLIMAB FOR PREVIOUSLY UNTREATED SUBJECTS WITH INTERMEDIATE TO VERY HIGH-RISK MYELODYSPLASTIC SYNDROMES... by Amer M. Zeidan, Karen Mosher, Sonia Souza, Beloo Mirakhur, Harold Keer, Jason Taylor

Get full text

P1293: COMBINING THE IAP ANTAGONIST, TOLINAPANT, WITH A DNA HYPOMETHYLATING AGENT ENHANCES ANTI-TUMOUR MECHANISMS IN PRECLINICAL MODELS OF T-CELL LYMPHOMA. by M. Sims, G. Ward, Z. Zhang, S. Jueliger, M. Davis, A. Boxall, J. Taylor, A. Biondo, J. Lyons, T. Smyth

Get full text

S217: PRELIMINARY ANALYSIS OF THE PHASE II STUDY USING TOLINAPANT (ASTX660) MONOTHERAPY IN 98 PERIPHERAL T-CELL LYMPHOMA AND 51 CUTANEOUS T-CELL LYMPHOMA SUBJECTS WITH RELAPSED REF... by J.-M. Michot, A. Mehta, F. Samaniego, E. Bachy, P. L. Zinzani, A. Prica, G. P. Colins, V Ribrag, N. Wagner-Johnston, D. El-Sharkawi, O. A. O’Connor, R. Wilcox, L. Wang, L. Wilson, M. Sims, J. A. Taylor, H. N. Keer, F. Foss

Get full text

PB2358: PHASE 1-2 STUDY OF THE SAFETY, PK, PD, AND PRELIMINARY ACTIVITY OF TOLINAPANT IN COMBINATION WITH ORAL DECITABINE/CEDAZURIDINE AND ORAL DECITABINE/CEDAZURIDINE ALONE IN SUB... by Jake Shortt, Brian Poligone, Vincent Ribrag, Pier Luigi Zinzani, Dima El-Sharkawi, Jan Walewski, Anca Prica, Laksmi Wilson, Sonia Souza, Harold Keer, Jason Taylor, Enrica Marchi

Get full text

P735: EFFICACY AND SAFETY OF ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN THE CMML SUBPOPULATION FROM PHASE 2 AND ASCERTAIN PHASE 3 STUDIES by Michael Robert Savona, James K Mccloskey, Elizabeth A. Griffiths, Karen Yee, Amer M. Zeidan, Aref Al-Kali, H. Joachim Deeg, Prapti A. Patel, Mitchell Sabloff, Mary-Margaret Keating, Nancy Y Zhu, Nashat Gabrail, Salman Fazal, Joseph J. Maly, Olatoyosi Odenike, Hagop Kantarjian, Amy Dezern, Casey L Oconnell, Gail Roboz, Lambert Busque, Rena Buckstein, Harshad Amin, Jasleen K Randhawa, Brian Leber, Kim-Hien Dao, Winny Chan, Aram Oganesian, Yuri Sano, Beloo Mirakhur, Harold Keer, Guillermo Garcia-Manero

Get full text

P1278: ACTIVATION OF THE NECROPTOSIS PATHWAY PLAYS A ROLE IN SYNERGISM WITH COMBINATION OF THE IAP ANTAGONIST, TOLINAPANT AND HYPOMETHYLATING AGENTS (HMA) IN IN VITRO MODELS OF T-C... by J. S. Manavalan, MD, I. Pal, PhD, A. Pursley, G. Ward, PhD, T. Smyth, PhD, M. Sims, PhD, D. Feith, PhD, T. P. Loughran, Jr, MD, O. A. O’Connor, MD, PhD, E. Marchi, MD, PhD

Get full text

P460: ERK1/2 INHIBITION OVERCOMES RESSITANCE TO BCL2 INHIBITION IN ACUTE MYELOID LEUKEMIA BY IMPACT ON MITOCHONDRIAL DYNAMICS AND FUNCTION by Priyanka Sharma, Sujan Piya, Natalia Baran, Anna Zal, Qi Zhang, Joanne Munck, Kim-Hien Dao, Martin Sims, Michael Andreeff, Gautam Borthakur

Get full text

P417: GENOMIC LANDSCAPE AND PROGNOSIS IN OLDER ACUTE MYELOID LEUKEMIA PATIENTS NOT ELIGIBLE FOR INTENSIVE CHEMOTHERAPY by Ekaterina Jahn, Maral Saadati, Pierre Fenaux, Marco Gobbi, Gail Roboz, Lars Bullinger, Pavlo Lutsik, Anna Riedel, Christoph Plass, Nikolaus Jahn, Claudia Walter, Karlheinz Holzmann, Yong Hao, Sue Naim, Nicholas Schreck, Julia Krzykalla, Axel Benner, Harold Keer, Mohammad Azab, Konstanze Döhner, Hartmut Döhner

Get full text

P768: GUADECITABINE (SGI-110) VS. TREATMENT CHOICE (TC) IN RELAPSED/REFRACTORY(R/R) MYELODYSPLASTIC SYNDROME (MDS), RESULTS OF A GLOBAL, RANDOMIZED, PHASE 3 STUDY. by G. Garcia-Manero, S. Bart, J. K. McCloskey, P. Fenaux, D. Selleslag, G. Reda, D. Valcárcel, V. Santini, J. Mayer, B. Xicoy, H. Yamaguchi, M. Lübbert, Y. Miyazaki, H. Keer, Y. Hao, M. Azab, H. Döhner

Get full text

P719: RANDOMIZED PHASE 1-2 STUDY TO ASSESS SAFETY AND EFFICACY OF LOW-DOSE (LD) ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS: IN... by Guillermo Garcia-Manero, Kimo Bachishvili, Elizabeth A. Griffiths, Amer M. Zeidan, Elie Traer, Lalit Saini, Harshad Amin, Sanjay Mohan, Michael Lübbert, Lori Maness-Harris, James M Foran, Dominik Selleslag, Blanca Xicoy Cirici, Daniel Aaron Pollyea, David Sallman, Aref Al-Kali, Jesus Berdeja, Haifa Kathrin Al-Ali, Nancy Y Zhu, Patricia Font Lopez, Guillermo Sanz Santillana, Valeria Santini, Habte A. Yimer, Larry D Cripe, Victor Priego, Olatoyosi Odenike, Bert Heyrman, David Valcarcel, Pankit Vachhani, Yuri Sano, Beloo Mirakhur, Aram Oganesian, Harold Keer, Abdulraheem Yacoub

Get full text

P573: PHARMACOKINETIC EXPOSURE EQUIVALENCE AND PRELIMINARY EFFICACY AND SAFETY FROM A RANDOMIZED CROSS OVER PHASE 3 STUDY OF AN ORAL HYPOMETHYLATING AGENT DEC-C COMPARED TO IV DECI... by K. Geissler, Z. Koristek, T. Bernal del Castillo, J. Novák, G. Rodriguez Macias, S. K. Metzelder, A. Illes, A. Nagy, J. Mayer, M. Arnan, M.-M. Keating, J. Krauter, M. Lunghi, N. Stefano Fracchiolla, U. Platzbecker, V. Santini, Y. Sano, A. Oganesian, H. Keer, M. Lübbert

Get full text

Leveraging omic features with F3UTER enables identification of unannotated 3’UTRs for synaptic genes by Siddharth Sethi, David Zhang, Sebastian Guelfi, Zhongbo Chen, Sonia Garcia-Ruiz, Emmanuel O. Olagbaju, Mina Ryten, Harpreet Saini, Juan A. Botia

Get full text

733 Phase 1 study of ultra-high concentration nitric oxide ablation in relapsed or refractory, unresectable, primary, or metastatic cutaneous and subcutaneous malignancies by Gavin Choy, David Greenberg, Amir Avniel, Amichay Meirovitz, Jedidiah Monson

A dynamic knowledge graph approach to distributed self-driving laboratories by Jiaru Bai, Sebastian Mosbach, Connor J. Taylor, Dogancan Karan, Kok Foong Lee, Simon D. Rihm, Jethro Akroyd, Alexei A. Lapkin, Markus Kraft

Get full text

Methylomic Signatures of High Grade Serous Ovarian Cancer by Horacio Cardenas, Fang Fang, Guanglong Jiang, Susan M. Perkins, Chi Zhang, Robert E. Emerson, George Hutchins, Harold N. Keer, Yunlong Liu, Daniela Matei, Kenneth Nephew

Get full text

Epigenetic priming enhances antitumor immunity in platinum-resistant ovarian cancer by Siqi Chen, Ping Xie, Matthew Cowan, Hao Huang, Horacio Cardenas, Russell Keathley, Edward J. Tanner, Gini F. Fleming, John W. Moroney, Alok Pant, Azza M. Akasha, Ramana V. Davuluri, Masha Kocherginsky, Bin Zhang, Daniela Matei

“…Lurie Comprehensive Cancer Center; Walter S. and Lucienne Driskill Immunotherapy Research funds; Astex Pharmaceuticals; Merck & Co.; National Cancer Institute (NCI), NIH grants CCSG P30 CA060553, CCSG P30 CA060553, and CA060553.…”
Get full text